Table 3. Summary of cost (US dollars) and outcome results in the base-case analysis.
| Strategy | Cost | Progression-free LYs | Overall LYs | QALYs | Incremental cost per QALY* |
|---|---|---|---|---|---|
| PC (control strategy) | 30,811 | 0.536 | 1.394 | 0.740 | |
| Crizotinib with PAP | |||||
| NGS panel tests | 31,388 | 0.581 | 1.450 | 0.780 | 14,384 |
| Multiplex PCR testing | 31,362 | 0.581 | 1.450 | 0.780 | 13,740 |
| Crizotinib without PAP | |||||
| NGS panel tests | 37,826 | 0.581 | 1.450 | 0.780 | 174,970 |
| Multiplex PCR testing | 37,800 | 0.581 | 1.450 | 0.780 | 174,327 |
* Comparing with Control strategy
LYs: life years; NGS: next-generation sequencing; PAP: patient assistance program; PC: pemetrexed plus cisplatin; QALY: quality-adjusted life-year; PCR: polymerase chain reaction